Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Clinical Trial to Evaluate an Approved ITP Therapy Targeting Spleen Tyrosine Kinase (SYK) for Prevention and Treatment of COVID-19 Related Complications

Wolfgang Dummer, MD, Vadim V. Markovtsov, PhD, Sandra Tong, MD, Esteban Masuda, PhD

Blood (2020) 136 (Supplement 1): 35.

https://doi.org/10.1182/blood-2020-141045

Published: 2020

Journal Articles

Long-Term Safety Profile of the Oral Spleen Tyrosine Kinase Inhibitor Fostamatinib in Immune Thrombocytopenia (ITP) and Other Diseases

Sandra Tong, MD, Robert P. Numerof, PhD, Jane Datangel, RN, Esteban Masuda, PhD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-140907

Published: 2020

Journal Articles

Potential Anti-Thrombotic Effect without Accompanying Hemorrhage with Fostamatinib Use in Patients with Immune Thrombocytopenia

Ivy Altomare, MD, Vadim V. Markovtsov, PhD, Leslie Todd, Dheepika Weerasinghe, PhD, Robert P. Numerof, PhD, Sandy Tong, MD, Esteban Masuda, PhD, James B. Bussel, MD

Blood (2019) 134 (Supplement_1): 4889.

https://doi.org/10.1182/blood-2019-126558

Published: 2019

Journal Articles

Prediction of Response to Fostamatinib Based on the Presence of Plasma Platelet Autoantibodies in Adult Patients with Immune Thrombocytopenia (ITP) — Exploratory Analyses from Phase 3 Studies

Vadim V. Markovtsov, PhD, Sothy Yi, Chi Young, Anne-Marie Duliege, MD MS, Esteban Masuda, PhD

Blood (2018) 132 (Supplement 1): 3766.

https://doi.org/10.1182/blood-2018-99-113705

Published: 2018

Journal Articles

Blockade of Mer By the Small Molecule Inhibitor R992 Inhibits Multiple Myeloma and Its Associated Bone Disease By Restoring the Perturbed Bone Homeostasis

Janik Engelmann, Isabel Ben Batalla, PhD, Hanna Taipaleenmäki, PhD, Kristoffer Riecken, PhD, Victoria Gensch, Sarina Paesler, Nikolaus Berenbrok, Maria Elena Vargas, Jonas Waizenegger, MD, Boris Fehse, PhD, Klaus Pantel, MD, PhD, Ihab S Darwish, PhD, Somasekhar Bhamidipati, PhD, Esteban Masuda, PhD, Carsten Bokemeyer, MD, PhD, Eric Hesse, MD, PhD, Sonja Loges, MD, PhD

Blood (2018) 132 (Supplement 1): 1922.

https://doi.org/10.1182/blood-2018-99-118273

Published: 2018

NARROW

Clinical Trial to Evaluate an Approved ITP Therapy Targeting Spleen Tyrosine Kinase (SYK) for Prevention and Treatment of COVID-19 Related Complications

Long-Term Safety Profile of the Oral Spleen Tyrosine Kinase Inhibitor Fostamatinib in Immune Thrombocytopenia (ITP) and Other Diseases

Potential Anti-Thrombotic Effect without Accompanying Hemorrhage with Fostamatinib Use in Patients with Immune Thrombocytopenia

Prediction of Response to Fostamatinib Based on the Presence of Plasma Platelet Autoantibodies in Adult Patients with Immune Thrombocytopenia (ITP) — Exploratory Analyses from Phase 3 Studies

Blockade of Mer By the Small Molecule Inhibitor R992 Inhibits Multiple Myeloma and Its Associated Bone Disease By Restoring the Perturbed Bone Homeostasis

Email alerts

ASH Publications

American Society of Hematology

Clinical Trial to Evaluate an Approved ITP Therapy Targeting Spleen Tyrosine Kinase (SYK) for Prevention and Treatment of COVID-19 Related Complications

Long-Term Safety Profile of the Oral Spleen Tyrosine Kinase Inhibitor Fostamatinib in Immune Thrombocytopenia (ITP) and Other Diseases

Potential Anti-Thrombotic Effect without Accompanying Hemorrhage with Fostamatinib Use in Patients with Immune Thrombocytopenia

Prediction of Response to Fostamatinib Based on the Presence of Plasma Platelet Autoantibodies in Adult Patients with Immune Thrombocytopenia (ITP) — Exploratory Analyses from Phase 3 Studies

Blockade of Mer By the Small Molecule Inhibitor R992 Inhibits Multiple Myeloma and Its Associated Bone Disease By Restoring the Perturbed Bone Homeostasis

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only